2,650
Views
3
CrossRef citations to date
0
Altmetric
Genetics

Clinical testing panels for ALS: global distribution, consistency, and challenges

ORCID Icon, , , , , , , , , , ORCID Icon, , , , , , ORCID Icon, , ORCID Icon, , , , , , , , , , , , , , , , , , ORCID Icon & show all
Pages 420-435 | Received 28 Sep 2022, Accepted 22 Jan 2023, Published online: 10 Mar 2023

References

  • Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci. 2019;13:1310.
  • Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, ITALSGEN Consortium, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323–30.
  • Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232–40.
  • Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, et al. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 2016;87:1024–30.
  • Singh N, Ray S, Srivastava A. Clinical Mimickers of Amyotrophic Lateral Sclerosis-Conditions We Cannot Afford to Miss. Ann Indian Acad Neurol. 2018;21:173–8.
  • Richards D, Morren JA, Pioro EP. Time to Diagnosis and Factors Affecting Diagnostic Delay in Amyotrophic Lateral Sclerosis. In: Araki T, ed. Amyotrophic Lateral Sclerosis. Brisbane, AU: Exon Publications. 2021.
  • Dharmadasa T, Scaber J, Edmond E, Marsden R, Thompson A, Talbot K, et al. Genetic testing in motor neurone disease. Pract Neurol. 2022;22:107–16.
  • Salmon K, Anoja N, Breiner A, Chum M, Dionne A, Dupre N, et al. Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23:305–12.
  • Shepheard SR, Parker MD, Cooper-Knock J, Verber NS, Tuddenham L, Heath P, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:510–8.
  • Chio A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, ITALSGEN Consortium, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry. 2014;85:478–85.
  • Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19:267–74.
  • Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics 2022;19:1248–58.
  • Vajda A, McLaughlin RL, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A, et al. Genetic testing in ALS: A survey of current practices. Neurology 2017;88:991–9.
  • Chen YP, Yu SH, Wei QQ, Cao B, Gu XJ, Chen XP, et al. Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population. J Med Genet. 2022;59:840–9.
  • Klepek H, Goutman SA, Quick A, Kolb SJ, Roggenbuck J. Variable reporting of C9orf72 and a high rate of uncertain results in ALS genetic testing. Neurol Genet. 2019;5:e301.
  • Rubinstein WS, Maglott DR, Lee JM, Kattman BL, Malheiro AJ, Ovetsky M, et al. The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res. 2013;41:(Database issue):D925–35.
  • Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:(Database issue):D980–5.
  • Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48:D835–D844.
  • Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, et al. Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. Am J Hum Genet. 2017;100:895–906.
  • Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, FALS Sequencing Consortium, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436–41.
  • Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, SLAGEN Consortium, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2016;48:1037–42.
  • Dekker AM, Diekstra FP, Pulit SL, Tazelaar GHP, van der Spek RA, van Rheenen W, et al. Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. Sci Rep. 2019;9:5931.
  • Smith BN, Topp SD, Fallini C, Shibata H, Chen HJ, Troakes C, et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med 2017;9:eaad9157.
  • Teyssou E, Muratet F, Amador MD, Ferrien M, Lautrette G, Machat S, et al. Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiol Aging 2021;99:102 e11–e20.
  • Sainouchi M, Hatano Y, Tada M, Ishihara T, Ando S, Kato T, et al. A novel splicing variant of ANXA11 in a patient with amyotrophic lateral sclerosis: histologic and biochemical features. Acta Neuropathol Commun. 2021;9:106.